HC Wainwright & Co. Initiates Coverage On Dyne Therapeutics with Buy Rating, Announces Price Target of $36
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating and a price target of $36.

February 20, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dyne Therapeutics receives a Buy rating and a $36 price target from HC Wainwright & Co., indicating a positive outlook.
The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a significant price target suggests a strong positive outlook for Dyne Therapeutics. This endorsement is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100